COMPANY PROFILE

Padlock Therapeutics

Explore full profile

Biological and therapeutic footprint of protein deimination by PADs.

Cambridge, United StatesFounded 2014Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2016

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

At a glance

Status: Acquired
Founded: 2014
Headquarters: Cambridge, United States
Employees: 7
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Autoimmune, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: X

Founder mafia, market maps, research and news connected to this company by Dealroom

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Mar 2016	$600M	$600M	Bristol-Myers Squibb	—
SERIES A✓Equity / VC	Dec 2014	$23M	$92M	Atlas Venture · Index Ventures	—

Padlock Therapeutics team growth

Padlock Therapeutics's team grew 0% over the past year.

1-year team growth0%

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CLCDI LabsThe Autoantibody Seromics Company and Creators of HuProt™ - the world’s most comprehensive protein microarray	Mayagüez, Puerto Rico	Operational	40	$3.3M	—
CBCan-Fite BioPharmaA biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities	Petah Tikva, Israel	Operational
APAcerta PharmaClinical research on cancer and autoimmune diseases	Oss, Netherlands	Acquired
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
NENeurosnapAdvanced bioinformatics tools for drug discovery, protein engineering, and molecular docking with secure, customizable solutions	Wilmington, United States	Operational
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational
3I310, Inc.Generative AI for large molecules	San Francisco, United States	Operational
MBMetaNovas BiotechCombines AI with cutting-edge science to decipher complex disease biology and discover effective medicines	Pudong, China	Operational